214 related articles for article (PubMed ID: 16264993)
1. Phase III trials in oncology: setting standards of care?
Seeber S; Braun AH
Nat Clin Pract Oncol; 2005 Sep; 2(9):426-7. PubMed ID: 16264993
[No Abstract] [Full Text] [Related]
2. Systemic therapy for metastatic urothelial carcinoma.
Lin CC; Hsu CH; Pu YS; Vogelzang NJ
BJU Int; 2008 Apr; 101(7):795-803. PubMed ID: 18070193
[No Abstract] [Full Text] [Related]
3. Clinical trials referral resource. Current phase II and phase III clinical trials in the treatment of colorectal cancer.
Mooney MM; Schoenfeldt M
Oncology (Williston Park); 2004 Oct; 18(11):1396, 1401, 1404 passim. PubMed ID: 15609469
[No Abstract] [Full Text] [Related]
4. Health care disparity: an overlooked problem in phase I oncology trials.
O'Brien TE
J Clin Oncol; 2007 Jul; 25(21):3182-3. PubMed ID: 17634502
[No Abstract] [Full Text] [Related]
5. Bladder cancer clinical trials.
Lerner SP
Urol Oncol; 2005; 23(4):275-9. PubMed ID: 16018944
[TBL] [Abstract][Full Text] [Related]
6. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
7. Comparison of outcomes of phase II studies and subsequent randomized control studies using identical chemotherapeutic regimens.
Zia MI; Siu LL; Pond GR; Chen EX
J Clin Oncol; 2005 Oct; 23(28):6982-91. PubMed ID: 16192585
[TBL] [Abstract][Full Text] [Related]
8. A multidisciplinary approach is required to increase the quality of phase II/III clinical studies on biotherapies in oncology.
Ottaiano A; Budillon A; Normanno N; Iaffaioli VR; Caraglia M
Ann Oncol; 2007 May; 18(5):960-1. PubMed ID: 17437968
[No Abstract] [Full Text] [Related]
9. Improving the institutional submission and approval process for clinical research protocols in oncology.
Camacho LH; Marubio L; Purdom MA; Leonard D; Hong DS; Moulder S; Pilat SR; Kurzrock R
J Clin Oncol; 2007 Apr; 25(12):1632-3. PubMed ID: 17443009
[No Abstract] [Full Text] [Related]
10. Clinical trials referral resource. Current clinical trials in rhabdomyosarcoma.
Anderson BD; Schoenfeldt M
Oncology (Williston Park); 2005 Sep; 19(10):1319-20, 1330. PubMed ID: 16285226
[No Abstract] [Full Text] [Related]
11. Magnitude of benefit of adjuvant chemotherapy for non-small cell lung cancer: meta-analysis of randomized clinical trials.
Bria E; Gralla RJ; Raftopoulos H; Cuppone F; Milella M; Sperduti I; Carlini P; Terzoli E; Cognetti F; Giannarelli D
Lung Cancer; 2009 Jan; 63(1):50-7. PubMed ID: 18565615
[TBL] [Abstract][Full Text] [Related]
12. Chemotherapy for recurrent cervical cancer.
Pectasides D; Kamposioras K; Papaxoinis G; Pectasides E
Cancer Treat Rev; 2008 Nov; 34(7):603-13. PubMed ID: 18657909
[TBL] [Abstract][Full Text] [Related]
13. [Non-small cell lung cancer (NSCLC): the evolution of neo-adjuvant chemotherapy in the last 15 years].
Santo A; Genestreti G; Fiorio E; Terzi A; Lonardoni A; Calabrò F; Campaldini B; Colaluca P; Molino A; Cetto GL
Recenti Prog Med; 2006 Apr; 97(4):211-8. PubMed ID: 16729492
[TBL] [Abstract][Full Text] [Related]
14. Time to include high-risk early ovarian cancer in randomized phase III trials of advanced ovarian cancer.
Vergote I; Amant F
Gynecol Oncol; 2006 Sep; 102(3):415-7. PubMed ID: 16979430
[No Abstract] [Full Text] [Related]
15. The phase III candidate: can we improve the science of selection?
Bajorin D
J Clin Oncol; 2004 Jan; 22(2):211-3. PubMed ID: 14665614
[No Abstract] [Full Text] [Related]
16. Eleven years: the long and winding road.
Ramondetta LM; Jhingran A
Gynecol Oncol; 2007 Nov; 107(2):166-8. PubMed ID: 17950382
[No Abstract] [Full Text] [Related]
17. Therapies in development for castrate-resistant prostate cancer.
Harzstark AL; Ryan CJ
Expert Rev Anticancer Ther; 2008 Feb; 8(2):259-68. PubMed ID: 18279066
[TBL] [Abstract][Full Text] [Related]
18. Incorporating novel treatment strategies into conventional therapy.
Estey EH
Clin Adv Hematol Oncol; 2009 Jun; 7(6):4-7. PubMed ID: 19645129
[No Abstract] [Full Text] [Related]
19. Changes in the natural history of nonsmall cell lung cancer (NSCLC)--comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990.
Wakelee HA; Bernardo P; Johnson DH; Schiller JH
Cancer; 2006 May; 106(10):2208-17. PubMed ID: 16604529
[TBL] [Abstract][Full Text] [Related]
20. Recent achievements and future developments in advanced and recurrent cervical cancer: trials of the Gynecologic Oncology Group.
Tewari KS; Monk BJ
Semin Oncol; 2009 Apr; 36(2):170-80. PubMed ID: 19332251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
